BIIB FY 2017 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

FY 2017 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$12.3B+7.2% YoY

Gross Profit

$10.6B86.7% margin

Operating Income

$5.3B43.6% margin

Net Income

$2.5B20.7% margin

EPS (Diluted)

$11.92

Cash Flow

Operating Cash Flow

$4.6B

Free Cash Flow

$3.7B

Stock-Based Comp.

$128M

Balance Sheet

Total Assets

$23.7B

Total Liabilities

$11.1B

Stockholders' Equity

$12.6B

Cash & Equivalents

$1.6B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12.3B	$11.4B	+7.2%
Gross Profit	$10.6B	$10.0B	+6.3%
Operating Income	$5.3B	$5.2B	+3.8%
Net Income	$2.5B	$3.7B	-31.4%